Abstract library

46 results for "Severi".
#671 Comparison of the Utility of Biochemical Markers in Predicting the Presence and Severity of Carcinoid Heart Disease
Introduction: Carcinoid heart disease (CHD) is a complication of metastatic neuroendocrine disease and is screened for using echocardiography.
Conference: 10th Annual ENETS Conference (2013)
Category: Biomarkers
Presenting Author: Dr Rebecca Dobson
Authors: Dobson R, Burgess M, Chadwick C, Vora J, ...
#2049 Identifying the Severity of Psychosocial Symptoms among Patients Diagnosed with Pancreatic Neuroendocrine Tumor. Do We Really Need Emotional Support Groups?
Introduction: Neuroendocrine tumors (pNETs) are the second most common neoplasm. Most of the pNETs are diagnosed at later stages among those patients who are underprivileged. The diagnosis and treatment of neuroendocrine tumor is a continuous emotional distress for both patient and their family.
Conference: 15th Annual ENETS conference (2018)
Category: Medical treatment - others, not specified
Presenting Author: Dr Arooj Fatima
Authors: Fatima A, Zai S S A, ...
#582 Comparison of biomarkers in predicting presence and severity of carcinoid heart disease in patients with metastatic mid-gut neuroendocrine tumours
Introduction: Carcinoid heart disease (CHD) is evaluated using echocardiography. The utility of plasma biomarkers for detecting the presence/severity of CHD is under-explored.
Conference:
Category: Clinical
Presenting Author: Dr Rebecca Dobson
#136 Prevalence, severity and clinical outcome of malnutrition in gastroenteropancreatic neuroendocrine tumors
Introduction: Malnutrition is well-known to unfavorably influence clinical prognosis in patients (pts) with malignant diseases. However, in patients with neuroendocrine tumors (NET) prevalence and outcome of malnutrition are unknown although the gastroenteropancreatic system is most frequently involved.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Mr Sebastian Maasberg
#1325 Detection within a Neuroendocrine Tumor of High Levels of B-Lymphocyte Stimulator (BLyS) Correlates with a Greater Disease Severity
Introduction: .
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: Dr. Franco Grimaldi
Authors: Grimaldi F, Motta C, Cipri C, Tonelli V, ...
Keywords: Tumor marker
#2078 Self-Reported Side Effects in Neuroendocrine Tumor (NET) Patients Prescribed Somatostatin Analogues – The Role for Specialist Dietitians and Nurses
Introduction: In practice, many patients with NETs report a change in symptoms after starting somatostatin analogues (SSA’s). Many health professionals and NET patient advocates have noticed that some of the side effects experienced by patients are more common than patient information literature suggests. It is therefore important to ask what and how severe experiences are, and compare to literature, to help raise awareness amongst NET health professionals.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Tara Whyand
Authors: Whyand T, Davies P, Bouvier C, ...
#40 Clinical and prognostic implications of the genetic diagnosis of hereditary NET syndromes in asymptomatic patients
Introduction: Neuroendocrine tumors (NETs) are rare neoplasms, heterogeneous, and with variable biological behavior. NETs can be sporadic or they can arise in complex endocrine hereditary syndromes such as Multiple Endocrine Neoplasias (MEN), Familial Paragangliomatosis (FPGL), Neurofibromatosis type 1 (NF1), von Hippel-Lindau Disease (VHL), Tuberous Sclerosis (TSC) and Carney Complex (CC). By performing genetic screening, patients with hereditary NETs can be identified before the development of tumors.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Antongiulio Faggiano
#43 Relationship between neuroendocrine tumor-related symptoms and RAND-36 health-related quality of life scores
Introduction: Neuroendocrine tumors (NETs) can secrete hormones that cause flushing and diarrhea (carcinoid syndrome) and disrupt health-related quality of life (HRQL).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Jennifer L Beaumont
Authors: Beaumont J L, Liu Z, Choi S, Yao J C, ...
#76 Role of contrast-enhanced ultrasonography in the differential diagnosis of the pancreatic and hepatic lesions
Introduction: Contrast-enhanced ultrasonography (CEUS) is a new promising tool for the characterization of pancreatic lesions. This technique allows for highlighting the micro-vascularization of a lesion, especially with the use of second generation contrast media, characterized by harmonic responses at low acoustic pressures. Pancreatic endocrine tumors (PET)s were reported to have a peculiar behavior at CEUS, consisting of a higher enhancement compared to normal pancreas in the arterial phase and a rapid washout.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Francesco Milone
#411 Efficacy of Peptide Receptor Radionuclide Therapy Treatment with 177Ludotatate in Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
Introduction: Peptide receptor radionuclide therapy with 177Lu-DOTATATE (177Lu-PRRT) has shown activity against advanced well-differentiated pancreatic neuroendocrine tumors (P-NET) in previous phase I/II studies.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr Giovanni Paganelli